By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem webinar on peptiligase enzymes for greener peptide API production
Bubendorf, Switzerland: –Peptide technology specialist Bachem’s latest online webinar will focus on using traceless ligation enzymes to promote greener production of peptide-based active pharmaceutical ingredients (APIs).
The webinar ‘The use of enzymes in the production of peptide APIs’ will be hosted online via the Zoom platform on April 21, commencing at 1730 EDT (UTC +2) and lasting approximately one hour.
Free to register
Registration for the event is free of charge and can be completed online (see Resources).
The webinar will discuss how enzymes can form key components in making manufacturing routes of active pharmaceutical ingredients (APIs) more sustainable and environmentally friendly.
It will focus on the use of peptiligase enzymes used for chemo-enzymatic peptide synthesis produced by Netherlands-based EnzyTag, who will co-host the webinar. These enable greener peptide syntheses.
Key developer questions
Discussion will focus on key questions for developers and manufacturers on the use of enzymes as part of cGMP regimes such as the control strategies and regulatory considerations that need to be taken into account and what risk assessments should be in place?
Detailed presentations will be delivered by EnzyTag BV CEO Dr. Leendert van den Bos and the company’s Business Development Consultant, Dr. Robert Naasz.
Facilitating and moderating the event will be Bachem AG Senior Business Development Manager, Bernd Raschack.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
Specializing in traceless ligation, EnzyTag’s mission is to develop improved synthetic route for the manufacture of peptide-based new chemical entities (NCEs), small proteins and peptide-containing (bio)conjugates using the peptiligase technology.
EnzyTag was founded in December 2018 as a spin-off from EnzyPep. EnzyTag is a private investment and venture capital-backed company located adjacent to the Chemelot campus in Nuth, in the south of The Netherlands.
The company was formed to develop Peptiligase Technology to enable more economical manufacturing of linear Peptide Drugs and Antibody Drug Conjugates (ADCs), offering easier entry into economic manufacturing processes for linear peptide drugs and small proteins. The technology’s potential extends further into areas such as macrocyles (cyclotides) and conjugated dual inhibitors.
Learn more at: https://enzytag.com/
Click on Bachem webinar ‘The use of enzymes in the production of Peptide APIs’ to register for the event.
Subscribe to Bachems Newsletter to receive the latest updates.